Literature DB >> 7526885

DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.

J A Plumb1, M Gerritsen, P Workman.   

Abstract

Aerobic sensitivity to indoloquinone EO9 has been shown to correlate with cellular levels of the two-electron reducing enzyme DT-diaphorase. However, little is known about the relative roles of one- and two-electron reducing enzymes in the hypoxic cytotoxicity of EO9. We have characterised a panel of 23 human tumour cell lines for both bioreductive enzyme activities and aerobic sensitivity to EO9. Eight cell lines were then selected for a comparison of aerobic and hypoxic sensitivities. Activities of DT-diaphorase showed a wide range (> 10,000-fold), while activities of the one-electron reducing cytochrome b5 and cytochrome P450 reductases were generally lower and showed only a 15- and 25-fold range respectively. The aerobic cytotoxicity of EO9 was clearly related to the cellular levels of DT-diaphorase (r = 0.87), with higher levels giving increased sensitivity, but not to the levels of one-electron reducing enzymes. In contrast, there was no relationship between sensitivity to BCNU, cisplatin or the bioreductive agent SR 4233 (tirapazamine) and activities of any of these reducing enzymes. Under hypoxic conditions sensitivity to EO9 was markedly increased in cell lines with low levels of DT-diaphorase activity, while cell lines with high levels show only a small increase in sensitivity. This is reflected by a clear correlation (r = 0.98) between cellular DT-diaphorase activity and the ratio of aerobic to hypoxic sensitivity to EO9. However, we have now for the first time demonstrated an inverse correlation (r = 0.93) between the cellular activity of DT-diaphorase and hypoxic sensitivity to EO9, that is sensitivity decreases with increasing DT-diaphorase activity. Moreover, this correlation was lost when cells were exposed to drug in the presence of dicoumarol, supporting an involvement of DT-diaphorase in this relationship. These observations question the previously straightforward role for DT-diaphorase in the metabolic activation of EO9. Whereas DT-diaphorase is associated with increased toxicity in air, it appears to reduce the cytotoxicity of EO9 in hypoxic conditions. This suggests either that the one-electron reduction product of EO9 metabolism, the semiquinone, is more toxic than the two-electron reduction product, the hydroquinone, or that the hydroquinone is not cytotoxic and aerobic toxicity is due to the transient appearance of the semiquinone upon back oxidation of the hydroquinone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526885      PMCID: PMC2033714          DOI: 10.1038/bjc.1994.461

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

Review 1.  DT-diaphorase and cancer chemotherapy.

Authors:  R J Riley; P Workman
Journal:  Biochem Pharmacol       Date:  1992-04-15       Impact factor: 5.858

2.  Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.

Authors:  S R Keyes; S Rockwell; A C Sartorelli
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

3.  Generation of hydroxyl radical by anticancer quinone drugs, carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, in the presence of NADPH-cytochrome P-450 reductase.

Authors:  T Komiyama; T Kikuchi; Y Sugiura
Journal:  Biochem Pharmacol       Date:  1982-11-15       Impact factor: 5.858

4.  Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors.

Authors:  D L Gustafson; C A Pritsos
Journal:  J Natl Cancer Inst       Date:  1992-08-05       Impact factor: 13.506

5.  Site-directed mutagenesis of rat liver NAD(P)H: quinone oxidoreductase: roles of lysine 76 and cysteine 179.

Authors:  Q Ma; K Cui; R W Wang; A Y Lu; C S Yang
Journal:  Arch Biochem Biophys       Date:  1992-05-01       Impact factor: 4.013

6.  Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177.

Authors:  H H Chen; J X Ma; G L Forrest; P S Deng; P A Martino; T D Lee; S Chen
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

Review 7.  Bioreductive mechanisms.

Authors:  P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

8.  Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression.

Authors:  E Smitskamp-Wilms; G J Peters; H M Pinedo; J van Ark-Otte; G Giaccone
Journal:  Biochem Pharmacol       Date:  1994-04-20       Impact factor: 5.858

9.  Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase.

Authors:  S S Pan; P A Andrews; C J Glover; N R Bachur
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

10.  In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.

Authors:  R M Phillips; P B Hulbert; M C Bibby; N R Sleigh; J A Double
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

View more
  14 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.

Authors:  Wen Cai; Mary Hassani; Rajesh Karki; Ervin D Walter; Katherine H Koelsch; Hassan Seradj; Jayana P Lineswala; Hamid Mirzaei; Jeremy S York; Fatemeh Olang; Minoo Sedighi; Jennifer S Lucas; Thomas J Eads; Anthony S Rose; Sahba Charkhzarrin; Nicholas G Hermann; Howard D Beall; Mohammad Behforouz
Journal:  Bioorg Med Chem       Date:  2010-01-25       Impact factor: 3.641

Review 3.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

4.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.

Authors:  Ayelet M Samuni; William DeGraff; Murali C Krishna; James B Mitchell
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

6.  Targeting hypoxia in the leukemia microenvironment.

Authors:  Juliana Benito; Zhihong Zeng; Marina Konopleva; William R Wilson
Journal:  Int J Hematol Oncol       Date:  2013-08-01

7.  Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Authors:  Eugene Manley; David J Waxman
Journal:  J Pharmacol Exp Ther       Date:  2012-11-28       Impact factor: 4.030

8.  DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours.

Authors:  A Marín; A López de Cerain; E Hamilton; A D Lewis; J M Martinez-Peñuela; M A Idoate; J Bello
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.

Authors:  S M Bailey; M D Wyatt; F Friedlos; J A Hartley; R J Knox; A D Lewis; P Workman
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.